Clinical applications of dendritic cell cancer vaccines

Oncologist

Volumn 4, Issue 2, 1999, Pages 140-144

  Baar, Joseph ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

EID: 0032952496     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.4-2-140     Document Type: Article

References (45)

1. Coley WD. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigius). London: John Bale & Sons Publishers 1909;1-48.
2. Rock KL, Fleischacker C, Gamble S. Peptide-priming of cytolytic T cell immunity in vivo using microglobulin as an adjuvant. J Immunol 1993;150:1244-1252.
3. Rotzschke O, Falk K, Deres K et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990;348:252-254.
4. Falk K, Rotzschke O, Stevanovic S et al. Allele specific motifs revealed by sequencing of self peptides eluted from MHC molecules. Nature 1991;351:290-296.
5. Kropshofer H, Max H, Muller CA et al. Self-peptide released from class II HLA-DR1 exhibits a hydrophobic residue contact motif. J Exp Med 1992;175:1799-1803.
6. Caux C, Liu YJ, Banchereau J. Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol Today 1995;16:2-4.
7. Peters JH, Gieseler R, Thiele B et al. Dendritic cells: from ontogenic orphans to myelomonocytic descendants. Immunol Today 1996;17:273-278.
8. + blood dendritic cells. Blood 1995;86:3295-3301.
9. + T cells. J Immunol 1995;154:5071-5079.
10. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
11. Inaba K, Steinman RM, Pack MW et al. Identification of proliferating dendritic cell precursor in mouse blood. J Exp Med 1992(b);175:1157-1167.
12. + blood progenitors for anticancer therapy. Exp Hematol 1995;23:1463-1471.
13. Maraskovsky E, Brasel K, Teepe M et al. Dramatic increase in the numbers of functionally mature dendritic cells in flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996;184:1953-1962.
14. Knight SC, Hunt R, Dore C et al. Influence of dendritic cells on tumor growth. Proc Natl Acad Sci USA 1985;82:4495-4497.
15. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996;183:7-11.
16. Paglia P, Chiodoni C, Rodolfo M et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996;183:317-322.
17. Zou JP, Shimizu J, Ikegame K et al. Tumor-immunotherapy with the use of tumor-antigen-pulsed antigen-presenting cells. Cancer Immunol Immunother 1992;35:1-6.
18. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic anti-tumor immunity. Nat Med 1995;1:1297-1302.
19. Celluzzi CM, Mayordomo JI, Storkus WJ et al. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-288.
20. Flamand V, Sornasse T, Thielemans K et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;23:605-610.
21. Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell-associated cytokines. J Exp Med 1996;183:87-97.
22. Zitvogel L, Couderc B, Mayordomo JI et al. IL-12 engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann New York Acad Sci 1996;795:284-293.
23. Peace DJ, Chen W, Nelson H et al. T cell recognition of transforming protein encoded by mutated ras proto-oncogenes. J Immunol 1991;146:2059-2065.
24. Fisk B, Blevins TL, Wharton JT et al. Identification of an immunodominant peptide of HER2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-2117.
25. Peoples GE, Goedegebuure PS, Smith R et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995;92:432-436.
26. Traversari C, van der Bruggen P, Luescher IF et al. A non-apeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-1458.
27. Boel P, Wildmann C, Sensi ML et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-175.
28. van den Eynde B, Peeters O, De Backer O et al. A new family of genes coding for an antigen recognized by cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-698.
29. Kawakami Y, Eliyahu S, Sakaguch K et al. Identification of the immunodominant peptides of MART-1 human melanoma antigen recognized by the majority of HLA-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-352.
30. + cytotoxic T lymphocytes. J Exp Med 1995;181:363-368.
31. Bakker ABH, Schreurs MWJ, de Boer AJ et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma derived tumor infiltrating lymphocytes. J Exp Med 1994;179:1005-1009.
32. Brichard V, Van Pel A, Wolfel T et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-495.
33. Lowry DR, Schiller JT. Papillomaviruses and cervical cancer: pathogenesis and vaccine development. J Natl Cancer Inst 1998;23:27-30.
34. DeLeo AB. p53-based immunotherapy of cancer. Crit Rev Immunol 1998;18:29-35.
35. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-55.
36. Tjoa B, Boynton A, Kenny G et al. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 1996;28:65-69.
37. Finn O, Jerome KR, Henderson RA et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 1995;145:61-89.
38. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998;46:82-87.
39. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-89.
40. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
41. Chakraborty NG, Sporn JR, Tortora AF et al. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother 1998;47:58-64.
42. Mukherji B, Chakraborty NG, Yamasaki S et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995;92:8078-8082.
43. Hu X, Chakraborty NG, Sporn JR et al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479-2483.
44. Salgaller ML, Tjoa BA, Lodge PA et al. Dendritic cell-based immunotherapy of prostate cancer. Crit Rev Immunol 1998;18:109-119.
45. Wen YJ, Ling M, Bailey-Wood R et al. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998;4:957-962.